[1] ARNOLD S V, ECHOUFFO-TCHEUGUI J B, LAM C S P, et al. Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR)[J]. Am Heart J, 2018, 203:25-29.
[2] MILDER T Y, STOCKER S L, SAMOCHA-BONET D, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease[J]. Eur J Clin Pharmacol, 2019,75(11):1481-1490.
[3] SCHEEN A J. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease[J]. Clin Pharmacokinet, 2015, 54(7):691-708.
[4] TONG L, ADLER S. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers[J]. Postgrad Med, 2018, 130(4):381-393.
[5] SATTAR N, MCLAREN J, KRISTENSEN S, et al. SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surpris and what were the likely mechanisms? [J]. Diabetologia, 2016, 59(7):1333-1339.
[6] STEVENS A L M, FERFERIEVA V A, BITO V, et al. Exercise improves cardiac function and attenuates insulin resistance in Dahl salt-sensitive rats[J]. Intern J Cardiol, 2015, 186:154-160.
[7] YANG W, MA J, LI Y, et al. Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: a randomized controlled trial[J]. J Diabetes, 2018, 10(7):589-599.
[8] CAI X, HAN X, LUO Y, et al. Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: a meta-analysis[J]. J Diabetes, 2015, 7(3):347-359. |
